HealthCare Roundtable Washington Update – October 25, 2018

Trump Administration Proposes New Models to Test Reimbursement Changes for Part B Drugs

Today, speaking at the Department of Health & Human Services in Washington, President Trump announced the Administration’s next phase of efforts to put pressure on drug prices, focusing on intravenous and other drugs administered with the help of a physician that account for about $28 billion in annual Medicare spending and that are growing at about 9% annually.

The proposal will have the Center for Medicare and Medicaid Innovation (CMMI) test three different models of reimbursement and negotiation for Part B drugs to work to curb spending. The Roundtable is monitoring the proposal closely and will provide a more detailed analysis in our next weekly.

Find more information on the announcement.